TNFSF10 and prostate cancer: We therefore evaluated a panel of prostate cancer cell lines, including PC-3, DU-145 and LNCap, for growth inhibition using different concentrations of sorafenib, Apo2L/TRAIL, mapatumumab or lexatumumab for 24 hours.